<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32980182</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature.</ArticleTitle><Pagination><StartPage>100.e9</StartPage><EndPage>100.e15</EndPage><MedlinePgn>100.e9-100.e15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2020.08.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(20)30270-0</ELocationID><Abstract><AbstractText>TANK-binding kinase 1 (TBK1) mutations are a recently discovered cause of disorders in the frontotemporal dementia (FTD)-amyotrophic lateral sclerosis (ALS) spectrum. We describe a novel L683&#x2217; mutation, predicted to cause a truncated protein and therefore be pathogenic, in a patient presenting with nonfluent variant primary progressive aphasia at the age of 65 years. Her disease progressed over the following years, leading to her being mute and wheelchair bound seven years into her illness. Brain imaging showed asymmetrical left-sided predominant atrophy affecting the frontal, insular, and temporal cortices as well as the striatum in particular. Review of the literature found 60 different nonsense, frameshift, deletion, or splice site mutations, including the newly described mutation, with data on clinical diagnosis available in 110 people: 58% of the cases presented with an ALS syndrome, 16% with an FTD-ALS overlap, 19% with a cognitive presentation (including behavioral variant FTD and primary progressive aphasia) and 4% with atypical parkinsonism. Age at onset (AAO) data were available in 75 people: mean (standard deviation) AAO was 57.5 (10.3) in those with ALS, which was significantly younger than those with a cognitive presentation (AAO&#xa0;= 65.1 (10.5), p&#xa0;= 0.008), or atypical parkinsonism (AAO&#xa0;= 68.3 (8.7), p&#xa0;= 0.021), with a trend compared with the FTD-ALS group (AAO&#xa0;= 61.9 (7.0), p=0.065); there was no significant difference in AAO between the other groups. In conclusion, clinical syndromes across the whole FTD-ALS-atypical parkinsonism spectrum have been reported in conjunction with mutations in TBK1. It is therefore important to include TBK1 on future gene panels for each of these disorders and to suspect such mutations particularly when there are multiple different phenotypes in the same family.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swift</LastName><ForeName>Imogen J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benotmane</LastName><ForeName>Hanya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woollacott</LastName><ForeName>Ione Oc</ForeName><Initials>IO</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafei</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK. Electronic address: j.rohrer@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M018288/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BRC149/NS/MH</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018888" MajorTopicYN="N">Aphasia, Primary Progressive</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Primary progressive aphasia</Keyword><Keyword MajorTopicYN="N">TBK1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>27</Day><Hour>20</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32980182</ArticleId><ArticleId IdType="pmc">PMC7907669</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.08.014</ArticleId><ArticleId IdType="pii">S0197-4580(20)30270-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad L., Zhang S., Casanova J., Sancho-Shimizu V. Human TBK1: a gatekeeper of neuroinflammation. Trends Mol. Med. 2016;22:511&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890605</ArticleId><ArticleId IdType="pubmed">27211305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso M., Modat M., Wolz R., Melbourne A., Cash D., Rueckert D., Ourselin S. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans. Med. Imaging. 2015;34:1976&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">25879909</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P., Camuzat A., De Septenville A., Couratier P., Lacomblez L., Auriacombe S. Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriers. Alzheimers Dement. (Amst.) 2015;1:481&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879495</ArticleId><ArticleId IdType="pubmed">27239526</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo M., Topp S., Smith B., Nishimura A., Chen H., Gkazi A. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging. 2018;71:266.e1&#x2013;266.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6983933</ArticleId><ArticleId IdType="pubmed">30033073</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., M&#xfc;ller K., Ludolph A., Weishaupt J., Andersen P. Association of mutations in TBK1 with sporadic and familial amyotrophic lateral sclerosis and frontotemporal dementia. JAMA Neurol. 2017;74:110&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">27892983</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18(5):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini M., Hillis A., Weintraub S., Kertesz A., Mendez M., Cappa S. Classification of Primary Progressive Aphasia and its Variants. Neurology. 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves C., Rohrer J. An update on genetic frontotemporal dementia. J.&#xa0;Neurol. 2019;266:2075&#x2013;2086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., Alfaify O., Hsiung G., Pottier C., Baker M., Perkerson R. Clinicopathologic correlations in a family with a TBK1 mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20(7&#x2013;8):568&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768716</ArticleId><ArticleId IdType="pubmed">31244341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Zhang J., Wu X., Cao L., Nie P., Chang M. TANK-binding kinase 1 (TBK1) isoforms negatively regulate type I interferon induction by inhibiting TBK1-IRF3 interaction and IRF3 phosphorylation. Front. Immunol. 2018;9:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797597</ArticleId><ArticleId IdType="pubmed">29441066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao B., Sun Q., Yuan Z., Wang J., Zhou L., Yan X., Shen L. Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort. Transl. Neurodegener. 2018;7:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278101</ArticleId><ArticleId IdType="pubmed">30534373</ArticleId></ArticleIdList></Reference><Reference><Citation>Koriath C., Bocchetta M., Brotherhood E., Woollacott I., Norsworthy P., Sim&#xf3;n-S&#xe1;nchez J. The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: a longitudinal case report. Alzheimers Dement. (Amst). 2016;6:75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5312484</ArticleId><ArticleId IdType="pubmed">28229125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb R., Rohrer J., Real R., Lubbe S., Waite A., Blake D. A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders. Cold Spring Harb. Mol. Case Stud. 2019;5:a003913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549548</ArticleId><ArticleId IdType="pubmed">31160356</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I., De Septenville A., Millecamps S., Camuzat A., Caroppo P., Couratier P. TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging. 2015;36:3116.e5&#x2013;3116.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476236</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Xie X., Wang Y., Liu J., Cheng X., Guo Y. Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins. Nat. Commun. 2016;7:12708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027247</ArticleId><ArticleId IdType="pubmed">27620379</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K., Nicholas J., Grossman M., McMillan C., Irwin D., Massimo L. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19:145&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007771</ArticleId><ArticleId IdType="pubmed">31810826</ArticleId></ArticleIdList></Reference><Reference><Citation>Morton S., Hesson L., Peggie M., Cohen P. Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. FEBS Lett. 2008;582:997&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307994</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes J., Davies M., Collins M. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Bieniek K., Finch N., van de Vorst M., Baker M., Perkersen R. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Neumann M., MacKenzie I. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 2012;8:423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer J., Warren J. Phenotypic signatures of genetic frontotemporal dementia. Curr. Opin. Neurol. 2011;24:542&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">21986680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan T., Tumbarello D. Optineurin: a coordinator of membrane-associated cargo trafficking and autophagy. Front. Immunol. 2018;9:1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962687</ArticleId><ArticleId IdType="pubmed">29867991</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R., Guennewig B., Dobson-Stone C., Kwok J., Kril J., Kiernan M. The underacknowledged PPA-ALS: a unique clinicopathologic subtype with strong heritability. Neurology. 2019;92:e1354&#x2013;e1366.</Citation><ArticleIdList><ArticleId IdType="pubmed">30770429</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J., Gijselinck I., Van Mossevelde S., Perrone F., Dillen L., Heeman B. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum. Mutat. 2017;38:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324646</ArticleId><ArticleId IdType="pubmed">28008748</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S., Van Der Zee J., Gijselinck I., Engelborghs S., Sieben A., Van Langenhove T. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139(Pt 2):452&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805085</ArticleId><ArticleId IdType="pubmed">26674655</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J., van der Zee J., Gijselinck I., Van den Bossche T., Dillen L., Heeman B. Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiol. Aging. 2018;62:245.e1&#x2013;245.e7. 245.e1-245.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29146049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C., Baets J., De Bleecker J., Deconinck T., Biskup S., Hayer S. Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol. Aging. 2018;62:244.e9&#x2013;244.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29137817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Yu W., Luo S., Yang Y., Liu F., Zhang Y. Association of the TBK1 mutation p.Ile334Thr with frontotemporal dementia and literature review. Mol. Genet. Genomic Med. 2019;7:e547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6418353</ArticleId><ArticleId IdType="pubmed">30672142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>